Urologic Clinics of North America (UROL CLIN N AM)

Publisher: WB Saunders

Journal description

Each issue of Urologic Clinics reviews new diagnostic and management techniques for a single clinical problem--and makes them simple to apply. Its concise, comprehensive, and its editors and authors are respected experts.

Current impact factor: 1.20

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 1.204
2013 Impact Factor 1.347
2012 Impact Factor 1.385
2011 Impact Factor 1.824
2010 Impact Factor 2.179
2009 Impact Factor 2.226
2008 Impact Factor 1.724
2007 Impact Factor 1.394
2006 Impact Factor 1.819
2005 Impact Factor 2.07
2004 Impact Factor 1.721
2003 Impact Factor 2.484
2002 Impact Factor 2.222
2001 Impact Factor 1.949
2000 Impact Factor 1.71
1999 Impact Factor 2.053
1998 Impact Factor 2.223
1997 Impact Factor 1.837

Impact factor over time

Impact factor

Additional details

5-year impact 1.36
Cited half-life >10.0
Immediacy index 0.49
Eigenfactor 0.00
Article influence 0.47
Website Urologic Clinics website
Other titles Urologic clinics of North America
ISSN 0094-0143
OCLC 944385
Material type Series, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details

WB Saunders

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Pre-print allowed on any website or open access repository
    • Voluntary deposit by author of authors post-print allowed on institutions open scholarly website including Institutional Repository, without embargo, where there is not a policy or mandate
    • Deposit due to Funding Body, Institutional and Governmental policy or mandate only allowed where separate agreement between repository and the publisher exists.
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Set statement to accompany deposit
    • Published source must be acknowledged
    • Must link to journal home page or articles' DOI
    • Publisher's version/PDF cannot be used
    • Articles in some journals can be made Open Access on payment of additional charge
    • NIH Authors articles will be submitted to PubMed Central after 12 months
    • Authors who are required to deposit in subject-based repositories may also use Sponsorship Option
    • Publisher last reviewed on 03/07/2015
    • 'WB Saunders' is an imprint of 'Elsevier'
  • Classification
    ​ green

Publications in this journal

  • Urologic Clinics of North America 08/2015; DOI:10.1016/j.ucl.2015.07.003
  • Urologic Clinics of North America 08/2015; DOI:10.1016/j.ucl.2015.05.011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Retroperitoneal lymph node dissection after chemotherapy has a proved role in the staging and treatment of metastatic testicular cancer. Complete removal of all postchemotherapy residual masses in nonseminomatous germ cell tumor should be performed. Complete removal of positron emission tomography-avid masses greater than 3 cm in pure seminoma should be performed. Outcomes depend on patient selection and extent of surgery. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.04.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Surgery remains an integral component of treating metastatic testicular germ cell tumors outside the retroperitoneum. Defining the role of surgery in extraretroperitoneal (ERP) disease can be challenging because metastases can vary in terms their volume, pattern, timing, and responsiveness to systemic therapy. Some of the philosophies on treating ERP disease have come from robust data on outcomes following postchemotherapy retroperitoneal lymph node dissection. The remaining knowledge is gained from retrospective series of different ERP sites from institutions with expertise in treating testis cancer. This article describes how ERP surgery should be integrated into a multidisciplinary treatment plan. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.04.011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Germ cell tumors of the testis have an overall survival rate greater than 90% as a result of a successful multidisciplinary approach to management. Late relapse affects a subset of patients however, and tends to be chemorefractory and the overall prognosis is poor. Surgery is the mainstay in management of late relapse but salvage chemotherapy can be successful. In this review, the clinical presentation and detection of late relapse, clinical outcomes, and predictors of survival in late relapse and the importance of a multidisciplinary treatment approach for successful management of late relapse are discussed. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.04.010
  • [Show abstract] [Hide abstract]
    ABSTRACT: Testicular germ cell cancer is one of the most curable cancers. Most patients are treated during their reproductive years, making infertility a significant quality of life issue after successful treatment. This focused review evaluates the factors that contribute to infertility and specific fertility risks with the various testicular cancer treatments. Timing of patient discussions and current fertility treatments are reviewed. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.05.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Testis cancer is the most commonly diagnosed cancer in young men. Most cases represent sporadic occurrences. Most commonly it presents at an early stage (clinical stage I) and is highly curable with radical orchiectomy. Even more advanced stages of testicular cancer are curable with a multimodality treatment approach. There are no widely accepted screening strategies for germ cell tumors. This article discusses the known risk factors and epidemiology of testis cancer, the presentation, and work up for new patients, and the prognosis and cure rates based on the staging and current treatment modalities for testis cancer patients. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.04.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: Second malignant neoplasms, cardiovascular disease, neurotoxicity and ototoxicity, pulmonary complications, hypogonadism, and nephrotoxicity are potentially life-threatening long-term complications of testicular cancer and its therapy. This article describes the pathogenesis, risks, and management of these late effects experienced by long-term testicular cancer survivors, who are defined as individuals who are disease free 5 years or more after primary treatment. Testicular cancer survivors should follow applicable national guidelines for cancer screening and management of cardiovascular disease risk factors. In addition, health care providers should capitalize on the time of cancer diagnosis as a teachable moment to introduce and promote lifestyle changes. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.05.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: The evolution of retroperitoneal lymph node dissection technique and associated template modifications for nonseminomatous germ cell tumors have resulted in significant improvement in the long-term morbidity. Through the preservation of sympathetic nerves via exclusion from or prospective identification within the boundaries of resection, maintenance and recovery of antegrade ejaculation are achieved. Nerve-sparing strategies in early-stage disease are feasible in most patients. Postchemotherapy, select patients can be considered for nerve preservation. This article describes the anatomic and physiologic basis for, indications and technical aspects of, and functional and oncologic outcomes reported after nerve-sparing retroperitoneal lymphadenectomy in testicular cancer. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.04.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Management of testicular seminoma has benefited from numerous advances in imaging, radiotherapy, and chemotherapy over the last 50 years leading to nearly 100% disease-specific survival for low-stage seminoma. This article examines the evaluation and management of low-stage testicular seminoma, which includes clinical stage I and IIA disease. Excellent outcomes for stage I seminoma are achieved with active surveillance, adjuvant radiotherapy, and adjuvant single-agent carboplatin. Current areas of research focus on optimizing surveillance regimens and minimizing the morbidity and long-term complications of adjuvant treatment. Radiotherapy continues to be the primary treatment option for patients with clinical stage IIa disease. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.04.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with persistently elevated serum tumor markers should be monitored for marker kinetics and evaluated for nonviable cancer causes of marker elevation. Desperation postchemotherapy retroperitoneal lymph node dissection is performed in select patients following second-line chemotherapy. Adjuvant postoperative chemotherapy is not indicated in patients following second-line chemotherapy. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.04.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intratubular germ cell neoplasia (ITGCN) is a precursor lesion for testicular germ cell tumors, most of which are early stage. ITGCN is also associated with testicular cancer or ITGCN in the contralateral testis, leading to a risk of bilateral testicular malignancy. Testicular biopsy detects most cases, and orchiectomy is the treatment of choice in patients with unilateral ITGCN. Low-dose radiation therapy is recommended in patients with bilateral ITGCN or ITGCN in the solitary testis, but the long-term risks of infertility and hypogonadism need to be discussed with the patient. Rare histologies of primary testicular cancer are also discussed. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 06/2015; 42(3). DOI:10.1016/j.ucl.2015.04.002
  • Urologic Clinics of North America 05/2015; 42(2). DOI:10.1016/S0094-0143(15)00016-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Cancer Genome Atlas project has identified and confirmed several important molecular alterations that form the basis for tumorigenesis and disease progression in muscle-invasive bladder cancer. Profiling studies also have reported on validated biomarker panels that predict prognosis and may be used to identify patients who require more aggressive therapy. This article describes the major molecular alterations in muscle-invasive urothelial carcinoma, and how several of these are being investigated as targets for novel therapeutics. It also highlights studies that identify biomarkers for platinum sensitivity, and efforts to integrate targeted therapeutics and companion theranostics for personalized treatment of muscle-invasive bladder cancer. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 03/2015; 42(2). DOI:10.1016/j.ucl.2015.01.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite advances in the treatment of other genitourinary malignancies, no novel therapies have been approved by the US Food and Drug Administration for urothelial carcinoma (UC) in the last 20 years. To date, no clinical trials of targeted agents in UC have led to improvements in survival compared with cytotoxic therapy. This article outlines representative trials of targeted therapies in UC and discusses the significance of genetic preselection in trial design as a method to optimize responses to these agents, thus, hopefully expanding the armamentarium of treatment options against this lethal disease. Copyright © 2015 Elsevier Inc. All rights reserved.
    Urologic Clinics of North America 03/2015; 42(2). DOI:10.1016/j.ucl.2015.01.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Videourodynamics combines fluoroscopic voiding cystourethrography with multichannel urodynamics to better evaluate lower urinary tract symptoms. This article reviews current literature and guidelines outlining the indications for obtaining this specialized study as well as technique. Appropriate and judicious use of fluoro-urodynamics lends to improved diagnostic acumen in a well-selected patient population; however, clinicians must be mindful of the added cost, safety concerns, and limitations of its use.
    Urologic Clinics of North America 08/2014; 41(3). DOI:10.1016/j.ucl.2014.04.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Urodynamics is indicated for the evaluation of postprostatectomy incontinence unless an artificial urinary sphincter placement is the preferred option, as in cases of severe incontinence, prior radiation, or previous male sling or artificial urinary sphincter placement-when male sling is unlikely to achieve efficacy. Urodynamics should be performed only when there is a question it can answer that would affect treatment choice or outcome. Urodynamic findings of detrusor underactivity, overactivity, and reduced compliance are important considerations in deciding how best to treat postprostatectomy incontinence.
    Urologic Clinics of North America 08/2014; 41(3). DOI:10.1016/j.ucl.2014.04.002
  • Urologic Clinics of North America 01/2014; 41(1):xvii.
  • Urologic Clinics of North America 01/2014; 41(1):39–53.
  • Urologic Clinics of North America 01/2014; 41(1):145–161.